

DAFTAR PUSTAKA

- Ahmad T and Felker GM. 2012. 'Galectin-3 in heart failure: more answers or more questions?'. *J Am Heart Assoc*, pp. 1-3.
- Atabakhshian R, Kazerouni F, Raygan F. *et al.* 2014. 'Assessment of the relationship between galectin-3 and ejection fraction and functional capacity in the patients with compensated systolic heart failure'. *Int Cardiovasc Res J*, 8(4), pp. 143-147.
- Bosnjak I, Selthofer-Relatic K and Aleksandar V. 2015. 'Review article: prognostic value of galectin-3 in patients with heart failure', *Disease Markers*, vol 2015, pp. 1-6.
- de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A. *et al.* 2013. 'Galectin-3 in heart failure with preserved ejection fraction'. *Eur J Heart Fail*, 15, pp. 1095–1110.
- de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA. *et al.* 2011. 'Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction'. *Ann Med*, 43(1), pp. 60-68.
- Edellman F, Holzendorf V, Wachter R *et al.* 2015. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial *Eur J Heart Fail*, 17, pp. 214–223.
- Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M. *et al.* 2012. 'Galectin 3 complements BNP in risk stratification in acute heart failure'. *Biomarkers*, 17(8), pp. 706–713.
- Gutierrez C and Blanchard DG. 2004. 'Diastolic heart failure: challenges of diagnosis and treatment'. *Am Fam Physician*, 69(11), pp. 2609-2616.
- Hillis GS, Moller JE, Pellikka PA, Gersh BJ, Wright RS, *et al.* 2004. 'Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction'. *J Am Coll Cardiol*, 43(7), pp. 360-367.
- Knight B, Xue Y, Maisel AS, and de Boer RA. 2012. 'Galectin 3: newest marker of HF outcomes'. *Curr Emerg Hosp Med Rep*, 2, pp. 112–119.
- Lang M (ed), 2013. The American Society of Echocardiography Guidelines and Standards Reference Book, Morrisville.

- Lanuzzi JL and Mann DL. 2015. *Clinical assessment of heart failure*. in: RO Bonow, DL Mann, DP Zipes, P Libby and E Braunwald (eds). 'Braunwald's heart disease a text book of cardiovascular medicine', 10th ed, Elsevier Saunders, Philadelphia.
- Mann DL. 2015. *Management of patients with heart failure with reduced ejection fraction*. in: RO Bonow, DL Mann, DP Zipes, P Libby and E Braunwald (eds). 'Braunwald's heart disease a text book of cardiovascular medicine', 10th ed, Elsevier Saunders, Philadelphia.
- Maurer MS, Packer M and Burkhoff D. 2002. 'Diastolic heart failure'. *N Engl J Med*, 351, pp. 1143-1145.
- McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, *et al.* 2012. 'ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC'. *Eur J Heart Fail*, 14(8), pp. 803–869.
- Mohammed LA, Heba S, Gafar HS, Hussien, NR. 2014. 'Galectin-3 as early detector of heart failure in children with congenital acyanotic heart disease'. *Clin Med and Diag*, 4(5), pp. 90-98.
- Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, *et al.* 2009. 'Recommendations for the evaluation of left ventricular diastolic function by echocardiography'. *Eur Heart J*, 10, pp. 165-193.
- Paulus WJ, Brutsaert DL, Gillebert TC, Rademakers FE, Leite-Moreira AF. *et al.* 1998. 'How to diagnose diastolic heart failure'. *European Heart Journal*, 19, pp. 990–1003.
- Paulus JW, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE *et al.* 2007. 'How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology'. *Eur Heart J*, 28, pp. 2539-2550.
- R&D Systems, Inc. 2009. 'Quantikine[®]: Human Galectin-3 Immunoassay'. Catalog Number DGAL30. pp 1-15
- Seferovic JP, Lalic NM, Floridi F, Tesic M, Seferovic PM. *et al.* 2014. 'Structural myocardial alterations in diabetes and hypertension: the role of galectin-3'. *Clin Chem Lab Med*, 52(10), pp. 1499-1505.

- Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, and Januzzi JL. 2010. 'Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure'. *Eur J Heart Fail*, 12, pp. 826–832.
- Sharma UC, Pokharel S, van Brakel, van Berlo JH, Cleutjens, J. *et al.* 2004. 'Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction'. *Circulation*, 110, pp. 3121-3128.
- Stromberg A and Matterson J 2013. 'Gender differences in patients with heart failure. *Eur J Cardiovasc Nurs* ', 2(1), pp. 7-18.
- van Heerebeek L and Paulus WJ. 2014. 'Impact of comorbidities on myocardial remodeling and dysfunction in heart failure with preserved ejection fraction'. *SOJ Pharm. Pharm Sci*, 1(2), pp.1-20.
- Wiegers SE. 2011. 'Diastolic echo parameters meaningless numbers or crucial information?' *Circ Cardiovasc Imaging*. 4, pp. 460-462.
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, *et al.* 2013. '2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines'. *Circulation*, 128(16), pp. e240–319.
- Yu L and de Boer RA. 2012. *Role of galectin-3 pathways in the pathogenesis of cardiac remodeling and heart failure*. In: 'Cardiac remodeling: molecular mechanisms'. chap 3, pp. 38-51.
- Yu L, Ruifrok W, Meissner M, Bos EM, van Goor H, *et al.* 2013. 'Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis'. *Circ Heart Fail*, 6, pp. 107-117.
- Zile MR and Brutsaert DL. 2002. 'New concepts in diastolic dysfunction and diastolic heart failure: part 1: diagnosis prognosis, and measurements of diastolic function'. *Circulation*, 105, pp. 1387-1393.
- Zile MR and Brutsaert DL. 2002. 'New concepts in diastolic dysfunction and diastolic heart failure: part 2: causal mechanism and treatment'. *Circulation*, 105, pp. 1503-1508